Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 12/20 | 0.71 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.69 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.69 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | TOP1 | P11387 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7359713 | 0.85 | PDE4A (0.75) | PDE4APDE4DPDE4CPDE4BPDE3B | |
| SCHEMBL7363642 | 0.83 | PDE4A (0.87) | PDE4APDE4DPDE4CPDE4BPDE3B | |
| SCHEMBL8330861 | 0.82 | PDE4A (0.76) | PDE4APDE4DPDE4CPDE4BPDE3B | |
| SCHEMBL7361971 | 0.82 | PDE4A (0.60) | PDE4APDE4DPDE4CPDE4BPDE3B | |
| Pyridopyridazinone SCHEMBL31427009 | 0.82 | PDE4A (1.00) | PDE4APDE4DPDE4CPDE4BPDE3B | |
| Pyridopyridazinone SCHEMBL6637552 | 0.82 | PDE4A (1.00) | PDE4APDE4DPDE4CPDE4BPDE3B | |
| Pyridopyridazinone SCHEMBL31427010 | 0.82 | PDE4A (1.00) | PDE4APDE4DPDE4CPDE4BPDE3B | |
| SCHEMBL8697092 | 0.82 | PDE4A (0.75) | PDE4APDE4DPDE4CPDE4BPDE3B | |
| SCHEMBL7360388 | 0.82 | PDE4D (0.66) | PDE4APDE4DPDE4CPDE4BPDE3B | |
| Pyridopyridazinone SCHEMBL7367220 | 0.81 | PDE4A (0.98) | PDE4APDE4DPDE4CPDE4BPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1418896-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| WO-2003000343-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | VIVUS, INC. (US) | 2003-01-03 | — | — | WO | claimed |
| US-8399466-B2 | Composition for regenerative treatment of cartilage disease | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-03-19 | — | — | US | disclosed |
| US-8252794-B2 | Composition for regenerative treatment of cartilage disease | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20100226993-A1 | COMPOSITION FOR REGENERATIVE TREATMENT OF CARTILAGE DISEASE | TANABE SEIYAKU CO., LTD. | 2010-09-09 | — | — | US | disclosed |
| EP-2193808-A1 | Synergistic combination | Nycomed GmbH (DE) | 2010-06-09 | — | — | EP | disclosed |
| US-7659273-B2 | adminstering phosphodiesterase-4 inhibitor selected from 2,3-bis(hydroxymethyl)-6,7-diethoxy-1-[1-(2-methoxyethyl)-2-oxo-4-pyridyl]naphthalene or 2,3-bis(hydroxymethyl) -6,7-diethoxy-1-[2-(4-(3-pyridyl)-1(2H)-phthaladinon-2-yl)-4-pyridyl]naphthalene | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20080031958-A1 | adminstering phosphodiesterase-4 inhibitor selected from 2,3-bis(hydroxymethyl)-6,7-diethoxy-1-[1-(2-methoxyethyl)-2-oxo-4-pyridyl]naphthalene or 2,3-bis(hydroxymethyl) -6,7-diethoxy-1-[2-(4-(3-pyridyl)-1(2H)-phthaladinon-2-yl)-4-pyridyl]naphthalene | TANABE SEIYAKU CO., LTD. | 2008-02-07 | — | — | US | disclosed |
| EP-1849468-A2 | Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist | Nycomed GmbH (DE) | 2007-10-31 | — | — | EP | disclosed |
| US-20070155652-A1 | Composition for regenerative treatment of cartilage disease | TANABE SEIYAKU CO., LTD. | 2007-07-05 | — | — | US | disclosed |
| EP-1418896-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003024488-A2 | COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003000343-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | VIVUS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080031958-A1 | adminstering phosphodiesterase-4 inhibitor selected from 2,3-bis(hydroxymethyl)-6,7-diethoxy-1-[1-(2-methoxyethyl)-2-oxo-4-pyridyl]naphthalene or 2,3-bis(hydroxymethyl) -6,7-diethoxy-1-[2-(4-(3-pyridyl)-1(2H)-phthaladinon-2-yl)-4-pyridyl]naphthalene | PDE4A, PDE7A, PDE4B | PDE4A 1/4885PDE4D 4/4885PDE4C 7/4885 |
| US-20100226993-A1 | COMPOSITION FOR REGENERATIVE TREATMENT OF CARTILAGE DISEASE | PDE4B, PDE4A, PDE4C | PDE4A 2/4885PDE4D 6/4885PDE4C 3/4885 |
| US-20070155652-A1 | Composition for regenerative treatment of cartilage disease | PDE4B, PDE4A, PDE4C | PDE4A 2/4885PDE4D 6/4885PDE4C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.